Keyword: Securities and Exchange Commission
FDA slaps Akorn with warning letter following an inspection of its sterile injectables plant in Illinois.
The former Teva chairman was accused of working in sync with others to control "penny stocks," and sold them after questionable promotions.
A federal jury ruled Aveo's ex-CFO David Johnston made untrue statements about tivozanib and that he made money as a result.
Clovis Oncology may have ditched development of cancer treatment rociletinib years ago, but the drug will cost the company more than $20 million.
Nasdaq-listed Sinovac accused OrbiMed, 1Globe Capital and a buyer consortium led by Sinobioway of conspiring a hostile takeover.
Just three days after celebrating a new FDA approval for use of its cancer drug Rubraca, Clovis Oncology quietly disclosed bad news about a saga that dates back two years.
Did insider trading occur around Sanofi’s $11.6 billion deal for Bioverativ? The Securities and Exchange Commission thinks it may have.
As the number of pending talc cases continues to tick upward, Johnson & Johnson is maintaining its defensive winning streak.
BDO sifted through SEC filings to discover just what the top 100 life sciences companies are most worried about these days.
Mylan has received a Department of Justice subpoena into its opioid business, according to a quarterly securities filing.